Truqap

Truqap | Pfizer Intelligence | Humanexa

Regulatory Timeline

FDA, EMA, PMDA, and other regulatory milestones from linked signals and precedents.

FDAJun 16, 2026approval
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View detail
FDAJun 16, 2026safety_guidance
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
View detail
FDAJun 16, 2026safety_guidance
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Why this matters: sets a safety guidance precedent in the same sub-indication (breast cancer) as Roche; the same agency is already in play for this signal, so precedent weight is higher.
View detail
FDAJun 16, 2026safety_guidance
FDA AP — INQOVI (SUPPL)
Application NDA212576. Sponsor: TAIHO ONCOLOGY. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEDAZURIDINE, DECITABINE.
View detail
AstraZenecaJun 16, 2026near-term
Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU
The recommendation from the CHMP indicates a strong likelihood of approval, which could lead to rapid market entry and necessitate compliance with new treatment protocols.
View detail
FDAJun 16, 2026approval
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View detail
FDAJun 16, 2026approval
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View detail
AstraZenecaJun 16, 2026near-term
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
The approval of Datroway sets a precedent for TROP2-directed therapies, which may influence future regulatory pathways and approvals for similar agents in oncology.
View detail
FDAJun 16, 2026approval
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why this matters: sets a approval precedent in the same sub-indication (prostate cancer) as AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
View detail
FDAJun 16, 2026approval
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View detail
AstraZenecaJun 16, 2026near-term
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
The recommendation from the FDA ODAC is a critical step towards final approval, which could enhance AstraZeneca's positioning in the oncology market and set a precedent for future targeted therapies.
View detail
AstraZenecaJun 16, 2026near-term
Truqap approved in US for PTEN-deficient metastatic prostate cancer
The approval signifies a successful regulatory pathway for a novel treatment, which may encourage further investment and development in targeted therapies for prostate cancer, influencing future regulatory strategies.
View detail

Evidence Sources

Source-backed references used to construct this page.

FDA AP — INQOVI (SUPPL)
FDA
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDA
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDA
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDA
FDA document
View source
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
ClinicalTrials.gov
FDA document
View source
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
ClinicalTrials.gov
FDA document
View source
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
ClinicalTrials.gov
FDA document
View source
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
ClinicalTrials.gov
FDA document
View source
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
ClinicalTrials.gov
FDA document
View source
MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial
ClinicalTrials.gov
FDA document
View source
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
ClinicalTrials.gov
FDA document
View source
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
ClinicalTrials.gov
FDA document
View source
Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression.
PubMed
FDA document
View source
Ubiquitination-anchored signature defines neuroendocrine prostate cancer: hub genes and single-cell ecosystem insights from integrated bioinformatics analysis of public transcriptomic datasets.
PubMed
FDA document
View source
Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.
PubMed
FDA document
View source
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.
PubMed
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMed
FDA document
View source
Polyploid giant cancer cells: the hidden players in ovarian cancer progression and prognosis.
PubMed
FDA document
View source
TGFA promotes the development of cervical cancer via interacting with DSG2.
PubMed
FDA document
View source

Truqap

Asset Overview

Company Context

Regulatory Timeline

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

FDA AP — INQOVI (SUPPL)

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Related Signals

Competitive Intelligence

Evidence Sources